Key Insights From the 2025 World Drug Safety Congress Europe

The landscape of drug safety is undergoing a crucial transformation, shaped by technological innovation, evolving regulatory requirements, and a growing emphasis on patient perspectives. These influences were investigated at the 2025 World Drug Safety Congress EU, held in Amsterdam, Netherlands, on October 7 and 8. Convening over 1800 global leaders and experts, the conference centered on addressing key challenges for safety professionals, highlighting how emerging technologies are redefining drug safety practices and improving patient outcomes across all health care systems.

Artificial Intelligence: A Transformative Tool in Pharmacovigilance

Artificial intelligence (AI) was among the most widely discussed topics at the congress, with major pharmaceutical companies sharing their real-world implementation experiences. In the sessions entitled “Automation Panel: Impacts of AI & Automation on Signal Detection” and “Operationalizing AI: Turning Innovation into Everyday Excellence,” industry leaders agreed on a central point: although AI is a powerful tool that can significantly strengthen pharmacovigilance operations, it is not expected to replace human expertise.

The advantages of AI in drug safety are substantial. By automating routine and time-consuming tasks, AI enhances productivity and enables safety professionals to focus on higher-value activities. Current AI applications, such as adverse event (AE) summarization, causality assessment, and automated data entry, demonstrate measurable improvements in both speed and accuracy; however, integration is accompanied by unique challenges. Speakers raised concerns regarding data privacy and the critical necessity to use company-approved tools. Standardizing AI-driven signal validation across the industry remains difficult, and there is growing concern that rapid AI use may widen the gap between high- and low-resource organizations.

Across discussions, one message remained consistent: AI should strengthen professional judgment, not replace it.

Evolution in Risk Management

Risk management discussions reflected a significant shift toward life cycle approaches and patient-centered decision-making. Rather than viewing benefit-risk assessment as a single point-in-time exercise conducted at regulatory submission, industry leaders emphasized the importance of continuous evaluation and vigilance throughout a product's life cycle in the sessions “Benefit Risk Evaluations: Views from CIOMS XII” and “Risk Management Panel – Implementing Benefit-Risk Frameworks: Engaging Patients and New Tools.”

This approach encourages embedding benefit-risk thinking early in drug development, guiding clinical trial design, end point selection, and evidence generation, while prioritizing patient perspectives on meaningful benefit, acceptable risk, and the delicate balance between efficacy and safety. Adopting “living, updatable” benefit-risk assessment documents was highlighted as best practice, which will enable organizations to reassess risks proactively to manage life cycle changes more effectively. Extending safety management teams across functional areas further supports this collaborative, patient-focused model, as shown in the session.

Signal Detection and Real-World Evidence

Real-world evidence has become an essential adjunct to traditional clinical trial data, as discussed in the session “Signal Detection & Management Panel: Strengthening Signal Management With Real World Data and Evidence.” By capturing long‑term outcomes and rare events across diverse patient populations and treatment settings, it enables more robust signal detection than is often possible in controlled studies. Such signals help identify safety signals that might otherwise go undetected, particularly for AEs that occur infrequently or emerge only after extended exposure.

However, the speakers cautioned that real-world data carry inherent limitations, including data quality and completeness issues, the potential for confounding factors in nonrandomized settings, and standardization challenges across data sources. All these limitations require careful consideration from experts to maximize the value of real-world evidence in pharmacovigilance.

Patient Centricity: Elevating the Patient Voice

Among all topics discussed, patient centricity generated the greatest enthusiasm and was discussed in sessions “Patient-Centric Pharmacovigilance: Elevating the Patient Voice in Pharmacovigilance” and “Enhancing Benefit-Risk Assessments With Patient Input: Strategies and Frameworks in Drug Development.” The FDA's Patient-Focused Drug Development Program¹ was highlighted as a leading model, using disease-specific meetings with patients, caregivers, and advocates to inform regulatory decision-making. Voice of the Patient reports² document these perspectives, helping contextualize clinical evidence and clarify acceptable risk levels for diseases.

Methods for capturing patient preferences ranged from qualitative approaches (eg, focus groups, patient advisory boards) to quantitative tools (eg, patient-reported outcomes, discrete choice experiments), but the benefits of incorporating patient input span the entire product life cycle: stronger clinical trial design, improved recruitment and retention, earlier safety signal identification, and better postapproval outcomes.

Patients have also offered direct guidance on improving AE reporting: simplified, user-friendly interfaces; better health care provider training in recognition and reporting; and confirmation that their reports were received and acted upon. As thoughtfully noted by one speaker, “The patient's voice is not noise—it's our most important signal.”

Implications for Pharmacy Professionals

For pharmacy professionals, the insights from the 2025 World Drug Safety Congress EU indicate important shifts in the monitoring and management of drug safety. As frontline health care providers with routine patient contact, pharmacists are uniquely positioned to improve AE reporting and serve as a crucial connection between patients and pharmacovigilance systems.

The emphasis on patient-centered approaches creates opportunities for pharmacists to play a role in capturing patient experiences. By educating patients on the importance of reporting AEs and facilitating simplified reporting, pharmacists can directly address the critical issue of AE underreporting. As AI and other digital tools are further integrated into pharmacovigilance, pharmacy professionals will also be required to develop competencies in working alongside these technologies while maintaining irreplaceable clinical judgment.

Conclusion

The future of pharmacovigilance will be defined by the thoughtful integration of technology with human expertise, a commitment to patient-centered approaches, and the recognition that drug safety is a continuum of learning and adaptation. The future of drug safety is dependent on collaboration, innovation, and a committed focus on the patient's voice.

REFERENCES

1. CDER Patient-Focused Drug Development. FDA. Updated March 2, 2026. Accessed April 6, 2026. https://www.fda.gov/drugs/development-approval-process-drugs/cder-patient-focused-drug-development

2. FDA-led Patient-Focused Drug Development (PFDD) public meetings. FDA. Updated March 21, 2026. Accessed April 6, 2026. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/fda-led-patient-focused-drug-development-pfdd-public-meetings